Cover Image
市場調查報告書

EpiCast Report:移植物對抗宿主疾病的流行病學預測

EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 307126
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:移植物對抗宿主疾病的流行病學預測 EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023
出版日期: 2014年07月01日 內容資訊: 英文 56 Pages
簡介

移植物對抗宿主疾病是隨著同種異體的造血幹細胞移植(HSCT)所產生的一般併發症,是由於移植處判斷移植進來的細胞是外部入侵而排斥所引發。根據症狀程度不同分為急性移植物對抗宿主病(aGVHD)及慢性移植物對抗宿主病(cGVHD),但雙方都對皮膚及消化道、肝臟、口腔黏膜、眼球等會造成不良影響。全球主要六國的aGVHD發病數,預測將由2013年的8,062件,到2023年增加到11,568件。此外,cGVHD的發病數也推計將由2013年的7,359件,到2023年增加到10,485件。

本報告提供全球主要6個國家(美國·法國·德國·義大利·西班牙·英國)的移植物對抗宿主疾病(GVHD)發病情形和今後預測相關分析,提供疾病的特徵(風險要素和主要的共生病症等)全球各國的趨勢,目前患病者的發病情形,今後10年的發病·患病數量之預測值等調查評估。

第1章 目錄

第2章 簡介

  • 概要
  • 相關調查
  • 近日出版的相關調查

第3章 流行病學

  • 疾病的背景
  • 風險要素和共生病症
  • 全球的趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 移植物對抗宿主疾病(GVHD)的流行病學的預測(今後10年份)
    • 確診的發病數量:造血幹細胞移植(HSCT的)情況
    • 確診的發病數量:自體HSCT的情況
    • 確診的發病數量:同種異體HSCT的情況
    • 確診的發病數量:急性移植物對抗宿主疾病(aGVHD的)情況
    • aGVHD已診斷的4年患病人數
    • 確診的發病數量:慢性移植物對抗宿主疾病(cGVHD的)情況
    • cGVHD已診斷的5年患病人數
  • 議論
    • 流行病學性的預測相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER064-14

Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35% during the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in 2023, at an AGR of 4.25% during the forecast period.

To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM, GlobalData epidemiologists selected nationally-representative studies that provided the diagnosed incidence of aGVHD and cGVHD using the uniform validated diagnostic criteria and classification defined by the Center International Blood and Marrow Transplant Research standard grading system for aGVHD, and the standard criteria for cGVHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGVHD and cGVHD cases. Another strength of this analysis is that the same methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed incident GVHD cases.

Scope

  • The Graft-Versus-Host Disease (GVHD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of hematopoietic stem cell transplantations (HSCTs) (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incident cases of GVHD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). GlobalData epidemiologists also forecast the four-year diagnosed prevalent cases of acute GVHD (aGVHD) and the five-year diagnosed prevalent cases of chronic GVHD (cGVHD) in the 6MM.
  • The GVHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global GVHD market.
  • Quantify patient populations in the global GVHD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the groups that present the best opportunities for GVHD therapeutics in each of the markets covered.
  • Identify the number of incident and prevalent aGVHD and cGVHD cases.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for GVHD (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of HSCTs
    • 3.5.2. Diagnosed Incident Cases of Autologous HSCTs
    • 3.5.3. Diagnosed Incident Cases of Allogeneic HSCTs
    • 3.5.4. Diagnosed Incident Cases of aGVHD
    • 3.5.5. Four-Year Diagnosed Prevalent Cases of aGVHD
    • 3.5.6. Diagnosed Incident Cases of cGVHD
    • 3.5.7. Five-Year Diagnosed Prevalent Cases of cGVHD
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Intrim Director of Epidemiology
    • 4.2.4. Global Director of Epidemiology (Through May 2014)
    • 4.2.5. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for GVHD
  • Table 2: 6MM, Sources of HSCT, aGVHD, and cGVHD Data Used for the Forecast
  • Table 3: 6MM, Sources Not Used in the Epidemiological Analysis of GVHD
  • Table 4: 6MM, Diagnosed Incident Cases of HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 5: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 6: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 7: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Table 8: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 9: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Table 10: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023

List of Figures

  • Figure 1: Flow Chart of Derivation of aGVHD and cGVHD Patient Population in the 6MM
  • Figure 2: 6MM, Diagnosed Incident Cases of HSCTs , Both Sexes, All Ages, N, 2013-2023
  • Figure 3: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 4: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 5: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023
  • Figure 6: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, 2013-2023
  • Figure 7: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
  • Figure 8: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023
Back to Top